Imugene (ASX:IMU) said efficacy data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with relapsed/refractory diffuse large B-cell lymphoma showed a best overall response rate of 79%, with 11 out of 14 patients showing a response to treatment, according to a Monday Australian bourse filing.
Two new patients became evaluable for responses, and both achieved a partial response, the filing said. The patients are being treated with azer-cel and interleukin 2.
The company is enrolling patients to the phase 1b azer-cel trial at 10 US sites, with up to six sites in Australia planned.
Imugene's shares jumped 10% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.